Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Global Market Report 2024 - By Trends, Size, Share, Trends, Forecast To 2033

The methicillin-resistant staphylococcus aureus (mrsa) drugs market size has grown strongly in recent years. It will grow from $2.26 billion in 2023 to $2.38 billion in 2024 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to antibiotic resistance concerns, hospital-acquired infections, surgical procedures, global increase in mrsa cases, high mortality rates.

The methicillin-resistant staphylococcus aureus (mrsa) drugs market size is expected to see strong growth in the next few years. It will grow to $2.9 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to continued antibiotic resistance challenges, advancements in mrsa diagnostics, global healthcare-associated infections, preventive measures in surgery, rising community-acquired mrsa cases.. Major trends in the forecast period include exploration of immunomodulators, strategic partnerships for drug development, customized therapies based on strain characteristics, focus on pediatric-specific formulations, global health initiatives to combat antibiotic resistance.

Market Overview -
Methicillin-resistant Staphylococcus aureus (MRSA) drugs refer to a group of drugs used to treat infections caused by the bacterium Staphylococcus aureus that are resistant to methicillin and other common antibiotics. These drugs are specifically chosen to target and kill MRSA bacteria or inhibit their growth. MRSA is a source of staph infections that is challenging to treat due to antibiotic resistance.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=10859&type=smp

Rise In Prevalence Of Methicillin-Resistant Staphylococcus Aureus Infections
The increase in the prevalence of methicillin-resistant Staphylococcus aureus infections is expected to propel the growth of the methicillin-resistant Staphylococcus aureus drugs market going forward. A methicillin-resistant Staphylococcus aureus (MRSA) infection is caused by Staphylococcus bacteria that is resistant to some antibiotics used for treating ordinary staph infections. MRSA infections must be treated with drugs that destroy and inhibit the growth of MRSA bacteria in humans and animals. For instance, in November 2022, according to the Centers for Disease Control and Prevention, a US-based health agency under the Department of Health and Human Services, hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) infections increased by 14% from 2020 to 2021. Further, in December 2022, according to a report by Statens Serum Institute, a Denmark-based sector research institute on MRSA - disease prevalence, in 2021, the number of community-acquired infections with recorded contact with a hospital or the nursing sector in the previous six months was 181, up from 159 in 2020. Therefore, the increase in the prevalence of methicillin-resistant Staphylococcus aureus infections is driving the growth of the methicillin-resistant Staphylococcus aureus drug market.

Competitive Landscape -
Major companies operating in the methicillin-resistant staphylococcus aureus (mrsa) drugs market report are Basilea Pharmaceutica Ltd., Merck & Co Inc., Pfizer Inc., Theravance Biopharma Inc., Allergan plc, Cumberland Pharmaceuticals Inc., Debiopharm International S.A., The Medicines Company, AbbVie Inc., Innovation Pharmaceuticals Inc., Melinta Therapeutics Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Absynth Biologics, AmpliPhi Biosciences Corporation, AstraZeneca plc, 3M Co., Meiji Seika Kaisha Ltd., GlaxoSmithKline plc, Johnson & Johnson, Sanofi S.A., Novartis, Wockhardt, Sun Pharmaceutical Industries Ltd., Lupin Limited, Glenmark Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Astellas Pharma Inc.

Driving Innovation In The Mrsa Drug Market With Breakthrough Treatment For Acute Bacterial Skin Infection
Product innovation is the key trend gaining popularity in the Methicillin-Resistant Staphylococcus aureus (MRSA) drug market. Major companies involved in the Methicillin-Resistant Staphylococcus Aureus (MRSA) drug market are focused on innovating new products to improve their observation power and sustain their position in the market. For instance, in March 2021, Melinta Therapeutics LLC, a US-based biopharmaceutical firm, announced the FDA approval of Kimyrsa (oritavancin), indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA). Kimyra is the first oritavancin one-hour infusion product prepared from one 1,200 mg vial and is compatible with both 0.9% sodium chloride injection (NS) and 5% dextrose in sterile water (D5W). The drug acts by inhibiting transpeptidation, inhibiting transglycosylation, and disrupting cell membrane integrity.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/methicillin-resistant-staphylococcus-aureus-mrsa-drugs-global-market-report

Key Segments -
The methicillin-resistant staphylococcus aureus (mrsa) drugs market covered in this report is segmented -
1) By Drug Class: Lipopeptides, Oxazolidinones, Cephalosporin, Tetracycline, Folate Antagonist, Lipoglycopeptide, Other Drug Classes
2) By Indication: Skin Infections, Bone and Joint Infections, Bacteremia, Animal Infections
3) By MRSA Type: Hospital-Acquired (HA-MRSA), Community-Acquired (CA-MRSA)
4) By Route of Administration: Oral Administration, Parenteral Administration
5) By End User: Hospitals and Clinics, Research and Academic Institutes, Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model"

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.